Neuroscientific Biopharmaceuticals Ltd. · ASX:NSB
Neuroscientific Biopharmaceuticals — TechKnow Invest Roadshow (August 2025)
16 slides from Neuroscientific Biopharmaceuticals's conference presentation, Aug 19, 2025
Slide 1: Patented Stem Cell Solutions for Complex Auto-Immune Disorders & Unmet Needs
ASXNSB For personal use only Patented Stem Cell Solutions for Complex Auto-Immune Disorders & Unmet Needs Nathan Smith – Chief Executive Officer TechKnow Invest Roadshow August 2025 1
Slide 2: Disclaimers
Disclaimers Forward Looking Statements For personal use only Presentation Information This presentation has been prepared by NeuroScientific Biopharmaceuticals Ltd (ASX: NSB) This presentation contains certain forward-looking statements that are based on the based on information available to it as a
Slide 3: For personal use only
ASXNSB Innovative biotechnology company, dedicated to developing novel technologies targeted at For personal use only immune-mediated inflammatory diseases. Specialising in the use of mesenchymal stem cells (MSCs) – adult stem cells that can reduce inflammation, promote the repair of tissue, and hel
Slide 4: Company Overview
Company Overview CORPORATE SHARE INFORMATION CAPITAL STRUCTURE & CASH ON HAND For personal use only AS AT 15 AUGUST 2025 ORDINARY SHARES PERFORMANCE SHARES OPTIONS SHARE PRICE A$0.18 CAPITAL 333.2 million 57.1 million 45.25 million MARKET CAPITALISATION ~A$60 million CASH ~$7.3 million SHARE PRICE C
Slide 5: Strength in Leadership & Advisory
Strength in Leadership & Advisory For personal use only Rob is a lawyer with over 35 years’ experience in corporate Dr Uvarov has significant experience in the healthcare industry with ROB MCKENZIE and commercial transactions, restructuring and dispute DR ANTON UVAROV a particular focus on neuroscie
Slide 6: What are Mesenchymal Stem Cells (MSC)?
ASXNSB What are Mesenchymal Stem Cells (MSC)? For personal use only MSC are adult stem cells, traditionally harvested from bone marrow, How Does Stem Cell but also able to be isolated from other tissues. Technology Work? MSC Stem cells are often called the “body's building blocks”, as they can poten
Slide 7: Industry News
ASXNSB Industry News For personal use only United States FDA recently approved the first mesenchymal stromal cell 1 United States FDA recently approved the first mesenchymal stromal cell (MSC) therapy (Mesoblast ASX Announcement 19.12.2024 (ASX: MSB - MSB market capitalisation as at 18 June 2025 of
Slide 8: Introducing StemSmart
Introducing StemSmart StemSmart early indications from the Phase 2 trial in refractory Crohn’s disease suggest that the For personal use only StemSmart MSC is potent, efficacious and safe1 High-quality product manufactured under StemSmart methodology StemSmart StemSmart is a global patented technolo
Slide 9: Cell Therapy for Serious Inflammatory Immune Disorders
Cell Therapy for Serious Inflammatory Immune Disorders For personal use only Mesenchymal Stem Cells (MSC) have a strong safety profile MSCs require an inflammatory environment to be StemSmartTM MSC are primed to respond to inflammation activated for clinical effect StemSmart o MSC work most effectiv
Slide 10: Stem Cell Technology for Refractory Crohn's
ASXNSB Stem Cell Technology for Refractory Crohn’s For personal use only What is Crohn’s Disease? StemSmart TM o Life-long chronic inflammation of the gut Refractory Crohn’s (life threatening) o Incurable affecting more than 1 million in Unresponsive to conventional therapies (Antibiotics/Steroids/B
Slide 11: Special Access Program
Special Access Program1 Commenced June 2025 For personal use only Crohn’s Fistulas o Commenced in June 20252 o <12 patients Treatment of patients with Crohn’s o Non healing fistulas Fistulas on compassionate grounds (SAS) o Administration of StemSmartTM at weekly intervals, for 4 weeks StemSmart o E
Slide 12: Product Pipeline & Market Size
Product Pipeline & Market Size Key Clinical Targets (StemSmartTM Addressable Markets) Forecast Increase Global Market For personal use only in Market ● Need for more effective treatments with less side effects US$13.8 billion Crohn’s ● Require additional treatment option for patients who have failed
Slide 13: Securing the StemSmart Supply Chain
ASXNSB Securing the StemSmart Supply Chain For personal use only • Partnership with Q-Gen Cell Therapeutics1 • Tech transfer has been initiated for NSB’s patented manufacturing process with targeting Phase 2 clinical trial supply by 2H CY 2026. • Q-Gen has a 13 cleanroom facility that has been licen
Slide 14: Upcoming Milestones
Upcoming Milestones For personal use only SAS Program progression StemSmart • Q4 2025: First 4 patients results announced Planned ≤12 patients treated with • Q2 2026: Full program completion and results announced clinical response results Phase 2 Clinical Trial Initiation • Q1 2026: CRO selection –
Slide 15: Key Corporate Factors
ASXNSB Key Corporate Factors For personal use only Global Crohn’s Patented SAS Fistulising Crohn’s Market Situation Technology Program Initiated Diversification Results pending The power of StemSmart StemSmart TM StemSmart holds significant Following the successful Phase 2 trial in refractory Divers
Slide 16: For further information, please contact
ASXNSB For personal use only For further information, please contact: Nathan Smith Chief Executive Officer +61 477 738 404 [email protected] Dr Anton Uvarov Founding Non-Executive Director +61 8 6268 2641 [email protected] 16
NeuroScientific Biopharmaceuticals — TechKnow Invest Roadshow (August 2025) on 6ix